Seroepidemiology of Toxoplasma gondii infection in the Israeli population

SUMMARY Toxoplasmosis seroprevalence varies considerably between countries. We studied the seoprevalence of Toxoplasma gondii IgG antibodies in a national sample of the Israeli population; 2794 sera were tested. The highest age-adjusted seroprevalence rate was in Arabs (non-Bedouins) (60·4%), significantly higher compared to the rate in Jews (19·9%) and Bedouins (27·5%) (P < 0·01). There were no significant gender differences. Seropositivity increased with age in all population groups. For Jews, seropositivity was associated with place of birth and socioeconomic status. A finding of low seroprevalence rate in Bedouins despite their poor living conditions and close contact with livestock is surprising, and might be attributed to the dry and hot climate conditions in their area of residence. In women of reproductive age the seroprevalence was 15·1% in Jews, 25·4% in Bedouins and 72·3% in Arabs (non-Bedouins). Thus, the majority of pregnant women are susceptible to primary infection with T. gondii, and the risk for congenital toxoplasmosis remains high.

[1]  R. Cristofani,et al.  A 4-year evaluation of toxoplasmosis seroprevalence in the general population and in women of reproductive age in central Italy , 2012, Epidemiology and Infection.

[2]  T. Ikenoue,et al.  Anti-Toxoplasma Antibody Prevalence, Primary Infection Rate, and Risk Factors in a Study of Toxoplasmosis in 4,466 Pregnant Women in Japan , 2011, Clinical and Vaccine Immunology.

[3]  J. Dubey,et al.  Seroepidemiology of Toxoplasma gondii infection in women from the North of Portugal in their childbearing years , 2011, Epidemiology and Infection.

[4]  B. Ataei,et al.  Seroepidemiology of Toxoplasma gondii infection in Isfahan province, central Iran: A population based study , 2011, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[5]  L. Mollema,et al.  Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in The Netherlands between 1995/1996 and 2006/2007 , 2010, Epidemiology and Infection.

[6]  M. Falagas,et al.  Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. , 2009, International journal for parasitology.

[7]  J. Desenclos,et al.  Toxoplasmosis among pregnant women in France: risk factors and change of prevalence between 1995 and 2003. , 2009, Revue d'epidemiologie et de sante publique.

[8]  C. Gorrini,et al.  Laboratory diagnosis of Toxoplasma gondii infection , 2009, International journal of medical sciences.

[9]  M. Abu-Madi,et al.  Seroprevalence and epidemiological correlates of Toxoplasma gondii infections among patients referred for hospital-based serological testing in Doha, Qatar , 2008, Parasites & Vectors.

[10]  C. Gorrini,et al.  Evaluation of Toxoplasma gondii Immunoglobulin G (IgG) and IgM Assays Incorporating the New Vidia Analyzer System , 2008, Clinical and Vaccine Immunology.

[11]  J. Montoya,et al.  Prevalence of infection with Toxoplasma gondii among pregnant women in Cali, Colombia, South America. , 2008, The American journal of tropical medicine and hygiene.

[12]  D. Kruszon-Moran,et al.  Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. , 2007, The American journal of tropical medicine and hygiene.

[13]  G. Bencaiova,et al.  Seroprevalence of Toxoplasma gondii antibodies in a healthy population from Slovakia. , 2006, European journal of internal medicine.

[14]  E. Rorman,et al.  Congenital toxoplasmosis--prenatal aspects of Toxoplasma gondii infection. , 2006, Reproductive toxicology.

[15]  I. Olafsson,et al.  Seroprevalence of Toxoplasma gondii in Sweden, Estonia and Iceland , 2006, Scandinavian journal of infectious diseases.

[16]  D. Spira,et al.  A cross-sectional survey of anti-Toxoplasma gondii antibodies in Jerusalem cats. , 2004, Veterinary parasitology.

[17]  D. Hill,et al.  Toxoplasma gondii: transmission, diagnosis and prevention. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  T. Navin,et al.  Toxoplasma gondii infection in the United States: seroprevalence and risk factors. , 2001, American journal of epidemiology.

[19]  B. Stray-Pedersen,et al.  Prevalence of Toxoplasma gondii specific immunoglobulin G antibodies among pregnant women in Norway , 1998, Epidemiology and Infection.

[20]  J. Condon,et al.  Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: evaluation of four commercial immunoassay systems , 1997, Journal of clinical microbiology.

[21]  R. Raz,et al.  Seroprevalence of antibodies against Toxoplasma gondii among two rural populations in northern Israel. , 1993, Israel journal of medical sciences.

[22]  Z. Dror,et al.  The prevalence and incidence of Toxoplasma antibodies in pregnant women. , 1993, Israel journal of medical sciences.

[23]  T. Swartz,et al.  Toxoplasmosis in Israel, 1970--73: evaluation of laboratory data. , 1978, Israel journal of medical sciences.

[24]  G. Araj,et al.  Seroprevalence of Toxoplasma antibodies among individuals tested at hospitals and private laboratories in Beirut. , 2010, Le Journal medical libanais. The Lebanese medical journal.

[25]  A. Mates,et al.  Prevalence of antibodies to Toxoplasma gondii in the Tel-Mond area. , 1993, Israel journal of medical sciences.